Academic Journal
Promising survival rate but high incidence of treatment‐related mortality after reduced‐dose craniospinal radiotherapy and tandem high‐dose chemotherapy in patients with high‐risk medulloblastoma
| العنوان: | Promising survival rate but high incidence of treatment‐related mortality after reduced‐dose craniospinal radiotherapy and tandem high‐dose chemotherapy in patients with high‐risk medulloblastoma |
|---|---|
| المؤلفون: | Lee, Ji Won, Lim, Do Hoon, Sung, Ki Woong, Cho, Hee Won, Ju, Hee Young, Hyun, Ju Kyung, Yoo, Keon Hee, Koo, Hong Hoe, Suh, Yeon‐Lim, Joung, Yoo‐Sook, Shin, Hyung Jin |
| المساهمون: | Ministry of Health and Welfare |
| المصدر: | Cancer Medicine ; volume 9, issue 16, page 5807-5818 ; ISSN 2045-7634 2045-7634 |
| بيانات النشر: | Wiley |
| سنة النشر: | 2020 |
| المجموعة: | Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: | Background In this study, we report the follow‐up results of reduced dose of craniospinal radiotherapy (CSRT) followed by tandem high‐dose chemotherapy (HDCT) in patients with high‐risk medulloblastoma (MB). Methods Newly diagnosed high‐risk MB patients (metastatic disease, postoperative residual tumor >1.5 cm 2 , or large cell/anaplastic histology) over 3 years of age were enrolled in this study. Two cycles of pre‐RT chemotherapy, radiotherapy (RT) including reduced‐dose CSRT (23.4 or 30.6 Gy), four cycles of post‐RT chemotherapy, and tandem HDCT were administered. NanoString and DNA sequencing were performed using archival tissues. Results In all, 40 patients were enrolled, and molecular subgrouping was possible in 21 patients (2 wingless, 3 sonic hedgehog, 8 Group 3, and 8 group 4). All patients including two patients who experienced progression during the induction chemotherapy underwent HDCT. Relapse/progression occurred only in four patients (5‐year cumulative incidence [CI] 10.4 ± 0.3%). However, six patients died from treatment‐related mortality (TRM) (four acute TRMs and two late TRMs) resulting in 18.5 ± 0.5% of 5‐year CI. Taken together, the 5‐year event‐free survival and overall survival were 71.1 ± 8.0% and 73.2 ± 7.9%, respectively. Late effects were evaluated in 25 patients and high‐tone hearing loss, endocrine dysfunction, dyslipidemia, and growth retardation were common. Conclusions The strategy using tandem HDCT following reduced‐dose CSRT showed promising results in terms of low relapse/progression rate; however, the high TRM rate indicates that modification of HDCT regimen and careful selection of patients who can benefit from HDCT will be needed in the future study. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1002/cam4.3199 |
| الاتاحة: | http://dx.doi.org/10.1002/cam4.3199 https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.3199 https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3199 https://onlinelibrary.wiley.com/doi/full-xml/10.1002/cam4.3199 |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.87259460 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/cam4.3199 |
|---|